Printer Friendly
The Free Library
23,389,518 articles and books


Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.

Aastrom Biosciences, Inc., Ann Arbor, MI, announced that the first clinical trial utilizing the company's proprietary Tissue Repair Cells (TRCs) to treat limb ischemia in diabetic patients has been initiated at the Diabetes Center at the Heart and Diabetes Center North Rhine-Westphalia (Diabetes Center) located in Bad Oeynhausen, Germany. Aastrom says initiation of the trial followed the Diabetes Center's receipt of the licenses and the Investigational Medicinal Product Dossier (IMPD) necessary to manufacture and use cells for clinical trials in compliance with the new European Union directives.

The aim of the study is to evaluate the safety and ability of Aastrom's bone marrow-derived TRCs to regenerate functioning blood vessels in the legs of diabetic patients with limb ischemia. The company says it is intended that the patients may experience relief from clinical problems that are related to a loss of blood circulation, such as: deep "bed-sore type" ulcerated wounds of the feet, pain, immobility, and infection.

Over the 12 months following treatment, the trial will evaluate whether the TRC treatment results in improved or complete healing of ulcers, as well as whether amputation can be avoided or delayed. The trial will also monitor the time to relapse if complete healing is not attended, and whether the prognosis for patient survival improves, compared to standard of care controls.

Contact: www.aastrom.com
COPYRIGHT 2005 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:clinical trials
Comment:Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.(clinical trials)
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 15, 2005
Words:221
Previous Article:Atrium Medical, Isotechnika announce licensing agreements for use of new drugs with medical devices.
Next Article:Biomedical Tissue Services being investigated for procuring tissues illicitly, falsifying testing records.
Topics:



Related Articles
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Reprogenesis acquires exclusive license to Children's Hospital/Harvard/MIT organ regeneration technology and product for bladder reconstruction.
Aastrom Biosciences signs agreement with Mathys Medical for German bone graft clinical trial.
MTF, Aastrom form partnership to develop novel treatments for tissue regeneration.
Aastrom Biosciences receives culture device European patent.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.
Aastrom receives patent expanding coverage for its single-pass perfusion technology.
Aastrom received FDA approval to initiate multi-center trial for bone graft product.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters